<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00798460</url>
  </required_header>
  <id_info>
    <org_study_id>IB-0809-055</org_study_id>
    <nct_id>NCT00798460</nct_id>
  </id_info>
  <brief_title>Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients</brief_title>
  <official_title>A Multicenter, Randomized, Controlled Tial of Combination Therapy for Lamivudine-resistant Chronic Hepatitis B Patient: Comparing Clevudine Plus Adefovir With Lamivudine Plus Adefovir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bukwang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Inje University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the optimal antiviral treatment for lamivudine
      resistant hepatitis B patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lamivudine with adefovir combination therapy has been known as effective antiviral therapy
      for lamivudine resistant chronic hepatitis B patients. It is superior to adefovir monotherapy
      since the incidence of viral breakthrough of combination therapy used to be less than that of
      adefovir monotherapy in lamivudine resistant chronic hepatitis B patients. Clevudine, which
      is being marketed in Korea, is a nucleoside analogue of the unnatural beta-L configuration
      that has potent activity against HBV. It has demonstrated potent antiviral efficacy and
      significant biochemical improvement after 24 weeks of therapy. We hypothesized that clevudine
      plus adefovir combination therapy for lamivudine resistant patients might be as effective as
      the lamivudine plus adefovir combination therapy.

      In detail, we designed to perform this clinical study comparing the combination of clevudine
      and adefovir with lamivudine plus adefovir in lamivudine resistant chronic hepatitis B
      patient. Total treatment duration of both groups will be 12 months, and compare the efficacy
      of antiviral effects of these drugs.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    could not enroll patients
  </why_stopped>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBV DNA titer &lt; 300 copies/mL</measure>
    <time_frame>48 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normalization of serum ALT, loss of HBeAg and HBsAg, incidence of adefovir resistance</measure>
    <time_frame>48 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Lamivudine plus adefovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Clevudine plus adefovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adefovir</intervention_name>
    <description>adefovir 10mg</description>
    <arm_group_label>Lamivudine plus adefovir</arm_group_label>
    <arm_group_label>Clevudine plus adefovir</arm_group_label>
    <other_name>Hepsera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clevudine</intervention_name>
    <description>clevudine 30mg</description>
    <arm_group_label>Clevudine plus adefovir</arm_group_label>
    <other_name>Levovir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lamivudine</intervention_name>
    <description>lamivudine 100mg</description>
    <arm_group_label>Lamivudine plus adefovir</arm_group_label>
    <other_name>Zeffix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HBsAg positive and anti-HBs negative more than 6 months

          -  YMDD mutation (+)during lamivudine therapy

          -  Serum ALT more than two times upper normal value

        Exclusion Criteria:

          -  HAV IgM Ab + and/or HCV Ab+ and/or HDV Ab and/or HIV Av+

          -  The sign of decompensated liver disease

          -  Pregnant or lactating woman

          -  The history of hemoglobinopathy, autoimmune hepatitis, alcoholic liver disease

          -  Hemoglobin less than 8 g/dL (male), 7.5g/dL (female) or neutrophil count less than
             1500/mm3 or platelet count less than 50,000/mm3

          -  Serum creatinine more than 1.5 times upper normal limit value

          -  The sign of malignancy or suggestive of malignancy or the history of malignancy, the
             recurrence rate within 2 years of which is more than 20%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>June Sung Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Ilsanpaik hospital, Inje Univeristy, 2240 Daewha-dong, Ilsanseo-gu, Goyang, Gyunggi, Korea, 411-706</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ilsanpaik hospital</name>
      <address>
        <city>Goyang</city>
        <state>Gyunggi</state>
        <zip>411-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2008</study_first_submitted>
  <study_first_submitted_qc>November 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2008</study_first_posted>
  <last_update_submitted>June 22, 2011</last_update_submitted>
  <last_update_submitted_qc>June 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>June Sung Lee</name_title>
    <organization>Ilsanpaik hospital, Inje University</organization>
  </responsible_party>
  <keyword>Chronic hepatitis B</keyword>
  <keyword>lamivudine resistance</keyword>
  <keyword>clevudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Clevudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

